Obesity is considered one of the greatest health challenges of our time. With drugs such as Ozempic, Wegovy and Mounjaro, new therapeutic approaches for effective weight loss have already achieved enormous success. But now, VK2735 is the focus of attention as a promising further development of this class of drugs. This book offers a comprehensive scientific examination of VK2735 and sheds light on all relevant aspects: its effect on metabolism, its influence on the hunger and satiety mechanism, and its potential advantages over established GLP-1 receptor agonists. How does VK2735 differ in terms of efficiency, tolerability and safety? What progress has been made in clinical development and when will the new drug be available? Based on current studies and analyses, it is clearly shown whether VK2735 has the potential to initiate the next revolution in the field of drug-based weight loss. A must-read for anyone who wants to gain a thorough understanding of the latest developments in obesity therapy.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.